mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. - sprookjes - yvandenbroek - TriplyDB

mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.

mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.

http://www.wikidata.org/entity/Q38794065

about

Targeting SOX2 as a Therapeutic Strategy in Glioblastoma Stratification and therapeutic potential of PML in metastatic breast cancer SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin NOS2 expression in glioma cell lines and glioma primary cell cultures: correlation with neurosphere generation and SOX-2 expression.Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.Oncogenic activity of SOX1 in glioblastoma Rapamycin promotes differentiation increasing βIII-tubulin, NeuN, and NeuroD while suppressing nestin expression in glioblastoma cells Current trends in mouse models of glioblastoma.mTOR-Dependent Cell Proliferation in the Brain.SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response.Identification of expression quantitative trait loci of MTOR associated with the progression of glioma.Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy.Role of miR-613 as a tumor suppressor in glioma cells by targeting SOX9.Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma TGF-β1 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2/3 signalling pathway Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer PR-LncRNA signature regulates glioma cell activity through expression of SOX factors

P2860

Q28079501-F0AC14A0-3CDE-4FA1-85A2-794B1A692B09 Q28387589-6646681B-B14F-45D5-B9C0-7FC186FCB607 Q28387834-E5D988F0-19B9-4E34-9125-5B1B40E075D6 Q33648954-1118C017-2F83-4296-92C8-052F09F33AA8 Q37691110-CBE15D50-3CB3-4394-A12D-631E55C37E0A Q41553115-F80E964A-6FD2-4DFB-81B0-FF162526F9B5 Q42153591-026F73D1-FF84-4F28-BD13-94029307BB6E Q42244908-BA3CF0E6-D704-45CA-8E64-2F5A9421E3A2 Q47169542-8324B815-3C3E-43B4-BB92-DE6A820E967E Q47231432-351D05BE-6EA6-45AC-8437-CF42F4CD0DA7 Q47445813-B69E5544-4B0E-40DA-957F-B37FCCFF22E0 Q48334668-74A7AEEB-4459-43CC-A8DB-1EE47DE844FD Q49190145-A0F758A1-3931-4EBD-842E-90A940BD3C83 Q50327117-7892C8C4-65E1-458E-96B6-6EFCB3B0AC7F Q55138983-ED48C05D-D063-4B52-B67C-36D7AAE652F1 Q57153312-F319B892-4314-4425-8EF5-9D835880BD5B Q57480178-CD8601C1-6FF6-4C93-85AC-A8C0AD2115D8 Q58695226-C03F2911-594A-44AC-919E-BDBAA4E2D9FE Q58708128-5ED20CD6-6C6F-43AA-8A7B-69DC50C43E41

P2860

mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.

http://www.wikidata.org/entity/Q38794065

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

mTOR inhibition decreases SOX2 ...... y and temozolomide resistance.

@en

type

label

mTOR inhibition decreases SOX2 ...... y and temozolomide resistance.

@en

prefLabel

mTOR inhibition decreases SOX2 ...... y and temozolomide resistance.

@en

P1433

Q38794065-6DEA4F50-F15B-4AA6-8A61-E6E905B805DB

P1476

Q38794065-5FA01AE5-2CA7-4C65-8BAA-D1FE316A98AF

P2093

Q38794065-00BD8759-8F93-448F-ABD5-838CAE241836

Q38794065-0FC6D98D-4F28-4222-B7CB-8CB494A7407A

Q38794065-21748CC7-097C-4E38-92BB-F5B4A42E0232

Q38794065-2912C385-E432-410B-86DB-66E74984F7D3

Q38794065-2D98E851-E8D7-4CF6-93EB-41C8B9348EB5

Q38794065-43A733BB-C490-4F23-9BB1-609FFBF2CED6

Q38794065-445ABC1A-81BE-4002-AF48-8614F9342C6E

Q38794065-4480FBDA-0795-4A80-BA76-6A9A8B69DA52

Q38794065-7E3F46F1-0CB7-4307-84D8-4816ACEE34ED

Q38794065-929F4972-7853-4A1C-BE82-66298A0EEE7F

P2860

Q38794065-005DE7EC-DC69-449D-9F61-6BD5DB8B006F

Q38794065-04E9516D-F991-476D-8D47-522ADF7198FC

Q38794065-0C33245C-1542-4B6F-94BC-A7A02ABEC498

Q38794065-0D2A43BA-5FBC-42D7-BB9F-208CCDE7188E

Q38794065-10057DFD-3CCE-4A1F-8A27-8A1C4A14A2DC

Q38794065-11BF69AF-E6B4-4B13-9B6A-9CB80B8D4140

Q38794065-13231C42-24EB-4410-91D1-D01798E7408C

Q38794065-14591227-4C8C-45AC-AEDD-2A7B1E19B7CB

Q38794065-2741CEA6-4EFA-4652-A008-4777A0736373

Q38794065-28ED6287-7E20-4CA1-86AD-36EC91551E96

P304

Q38794065-3C13E2CF-90CB-4017-9671-D683958FD3E7

P31

Q38794065-E16B9A7E-EC98-4BFB-A861-549CBBC0FB63

P356

Q38794065-9C08499D-097B-4976-BB10-71C9191D3F9D

P407

Q38794065-81CA2C0D-C4AE-435E-A9CF-8BAE2E6D9D1F

P433

Q38794065-AE433A98-FEB8-4C72-9B45-E8502F7EE5BB

P478

Q38794065-DAA0D011-00A2-4E27-87ED-63F1928D8181

P50

Q38794065-4E5581C6-F5BD-4918-95C3-25821C046466

P577

Q38794065-7F5ADD85-130B-4521-9C05-20C5B58AD33F

P698

Q38794065-E6309CED-9212-4BF6-9FA2-73FBD467627D

P932

Q38794065-C3E66BDA-99F3-475B-A7BD-4062EB36A9D4

P356

14728222.2016.1151002

P1433

Expert Opinion on Therapeutic Targets

P1476

mTOR inhibition decreases SOX2 ...... ty and temozolomide resistance

@en

P2093

Ander Matheu

http://www.w3.org/2001/XMLSchema#string

Cristina Barrena

http://www.w3.org/2001/XMLSchema#string

Estefania Carrasco-Garcia

http://www.w3.org/2001/XMLSchema#string

Idoia Garcia

http://www.w3.org/2001/XMLSchema#string

Irune Ruiz

http://www.w3.org/2001/XMLSchema#string

Jorge Villanua

http://www.w3.org/2001/XMLSchema#string

Laura Garros-Regulez

http://www.w3.org/2001/XMLSchema#string

Leire Moreno-Cugnon

http://www.w3.org/2001/XMLSchema#string

Nicolas Sampron

http://www.w3.org/2001/XMLSchema#string

Olatz Arrizabalaga

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Role of SOX family of transcription factors in central nervous system tumors

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Identification of human brain tumour initiating cells

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

The somatic genomic landscape of glioblastoma

The Sox9 transcription factor determines glial fate choice in the developing spinal cord

Multipotent cell lineages in early mouse development depend on SOX2 function

P304

393-405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2016.1151002

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Lorea Manterola

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26878385

http://www.w3.org/2001/XMLSchema#string

P932

4898154

http://www.w3.org/2001/XMLSchema#string